- ARIAD Pharmaceuticals (NASDAQ:ARIA) announces that partner Otsuka Pharmaceutical Company (OTCPK:OTSKF)(OTCPK:OTSKY) has received marketing approval in Japan for Iclusig (ponatinib) for the treatment of refractory chronic myeloid leukemia and relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
- The approval triggers a $10M milestone payment to ARIAD from Otsuka pursuant to their December 2014 collaboration agreement.
- Ponatinib is a multi-targeted tyrosine kinase inhibitor. It was approved in the U.S. for the treatment of two types of leukemia in December 2012.
- ARIA shares are up 2% premarket on light volume.